# Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma

> **NCT07277439** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 48 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **OTHER:** Radiochemoimmunotherapy
- **OTHER:** Immunomodulation

## Key facts

- **NCT ID:** NCT07277439
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-16
- **Primary completion:** 2027-02-16
- **Final completion:** 2029-02-16
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07277439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07277439, "Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT07277439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*